DBV Technologies (NASDAQ:DBVT) Given New $7.00 Price Target at HC Wainwright

DBV Technologies (NASDAQ:DBVT) had its price target raised by HC Wainwright from $5.00 to $7.00 in a report issued on Thursday, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for DBV Technologies’ FY2024 earnings at ($1.41) EPS, FY2027 earnings at ($1.06) EPS and FY2028 earnings at ($0.50) EPS.

Several other equities research analysts have also recently commented on DBVT. StockNews.com began coverage on shares of DBV Technologies in a research report on Monday, October 21st. They set a “hold” rating on the stock. JMP Securities reissued a “market outperform” rating and set a $5.00 price target on shares of DBV Technologies in a research report on Tuesday, September 24th.

DBV Technologies Stock Up 3.5 %

Shares of DBVT stock opened at $0.87 on Thursday. DBV Technologies has a 12-month low of $0.50 and a 12-month high of $2.28. The firm has a market capitalization of $83.61 million, a price-to-earnings ratio of -1.03 and a beta of 0.67. The firm has a fifty day moving average of $0.77 and a 200-day moving average of $0.95.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.08). The company had revenue of $1.16 million during the quarter, compared to the consensus estimate of $1.42 million. DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. During the same period in the prior year, the firm posted ($0.26) earnings per share. Research analysts expect that DBV Technologies will post -1.43 earnings per share for the current year.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. grew its holdings in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,568,909 shares of the company’s stock after buying an additional 327,345 shares during the quarter. DBV Technologies makes up 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th largest position. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.